Global Osteoarthritis Pain Market 2016-2020

Description: About the Osteoarthritis Pain Drugs Market
Osteoarthritis, the most common type of arthritis, is a leading cause of disability. It is a chronic, progressive degenerative joint disease, which is characterized by gradual destruction of the articular cartilage, hypertrophy of the bone margins, and a series of biochemical and morphological changes in the synovial membrane and joint capsule. This results in pain and loss of movement. It is also known as degenerative joint disease, hypertrophic arthritis, and degenerative arthritis, and is most commonly prevalent in older (above 60 years of age) and middle-aged people (between 40-59 years of age). The exact etiology of osteoarthritis is not well understood, but is believed to be an outcome of mechanical and molecular events in the affected joint. Increasing age, obesity, overuse of the joint, weak thigh muscles, and genetics are some of the common risk factors. Treatment is given depending upon the affected joint, including the hand, wrist, neck, back, knee, and hip, and involves medication and exercise.
The analysts forecast the global osteoarthritis pain drugs market to grow at a CAGR of 8.38% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global osteoarthritis pain drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used to treat osteoarthritis pain. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Osteoarthritis Pain Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Abbott Laboratories
- Johnson & Johnson
- Novartis International
- Pfizer

Other prominent vendors
- AbbVie
- Abiogen Pharma
- Afferent Pharmaceuticals
- Astellas Pharma
- BioDelivery Sciences International
- Crystal Genomics
- Cytori Therapeutics
- Daiichi Sankyo
- Eli Lilly
- Endo Pharmaceuticals Holdings
- Horizon Pharma
- iCeutica
- Iroko Pharmaceuticals
- Merck
- Nuvo Research
- Regeneron Pharmaceuticals
- Sanofi
- SantoSolve
- Techfields Pharma
- Winston Pharmaceuticals
- Yooyoung Pharmaceutical
- Zynerba Pharmaceuticals

Market drivers
- Significant unmet medical needs
- For a full, detailed list, view the full report

Market challenges
- Preference for alternative therapies
- For a full, detailed list, view the full report

Market trends
- Emergence of new treatments
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Contents:  
PART 01: Executive summary
- Highlights

PART 02: Scope of the report
- Market overview
- Assumptions
- Top-vendor offerings

PART 03: Market research methodology
- Research methodology
- Economic indicators

PART 04: Introduction
- Key market highlights
- Key buying criteria

PART 05: Disease overview
- Understanding osteoarthritis
- Etiology and pathophysiology
- Risk factors
- Signs and symptoms
- Diagnosis
- Disease management
- Surgical treatment
- Epidemiology
- Economic burden of osteoarthritis

PART 06: Pipeline portfolio
- Information on pipeline candidates
- Ampion
- Tanezumab
- Zilretta (FX006)
- Fasinumab
- IP 880
- SoluMatrix Naproxen
- ABT-981
- AF-219
- ASP7962

PART 07: Osteoarthritis pain drugs: Clinical trials

PART 08: Opportunities for research in osteoarthritis
- Gaps between current research and possible research issues
- Challenges for vendors involved in osteoarthritis drug development

PART 09: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis

PART 10: Market segmentation by drug class
- NSAIDs
- Opioids
- Viscosupplements
- Corticosteroids
- Others
- Global NSAIDs market
- Global opioids market
- Global viscosupplements market
- Global corticosteroids market

PART 11: Market segmentation by ROA
- Oral
- Parenteral
- Topical

PART 12: Market segmentation by dosage form
- Solid
- Liquid
- Semi-solid

PART 13: Geographical segmentation
- Osteoarthritis pain drugs market in Americas
- Osteoarthritis pain drugs market in US
- Osteoarthritis pain drugs market in EMEA
- Osteoarthritis pain drugs market in APAC

PART 14: Market drivers
- Significant unmet medical needs
- Promising drug pipeline
- Increase in prevalence of osteoarthritis and obesity

PART 15: Impact of drivers

PART 16: Market challenges
- Preference for alternative therapies
- Loss of patent exclusivity of branded therapies
- Adverse effects of drugs

PART 17: Impact of drivers and challenges

PART 18: Market trends
- Emergence of new treatments
- Use of off-label drugs
- Strategic alliances

PART 19: Vendor landscape
- Competitive scenario
- Abbott Laboratories
- Johnson & Johnson
- Novartis
- Pfizer
- Other prominent vendors

PART 20: Upcoming vendors with novel approaches
- Ampio Pharmaceuticals
- Flexion Therapeutics
- Kitov Pharmaceuticals

PART 21: Appendix
- List of abbreviations

PART 22: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria
Exhibit 03: Types of osteoarthritis
Exhibit 04: Etiology and pathophysiology of osteoarthritis
Exhibit 05: Signs and symptoms of osteoarthritis
Exhibit 06: Diagnostic test for osteoarthritis
Exhibit 07: Treatment options for osteoarthritis
Exhibit 08: Non-pharmacological therapies used for osteoarthritis
Exhibit 09: Pharmacotherapy therapy for osteoarthritis
Exhibit 10: Surgical treatment
Exhibit 11: Economic burden of osteoarthritis
Exhibit 12: Distribution of direct costs of osteoarthritis
Exhibit 13: Cost analysis of treatment for individuals with osteoarthritis
Exhibit 14: Pipeline molecules for osteoarthritis pain
Exhibit 15: Osteoarthritis clinical trials by development phase
Exhibit 16: Share of Phase I, II, and III pipeline candidates in osteoarthritis pain drugs market
Exhibit 17: Osteoarthritis clinical trials by trial status
Exhibit 18: Highlights of osteoarthritis research opportunities:
Exhibit 19: Global osteoarthritis pain drugs market 2015-2020 ($ billions)
Exhibit 20: Current opportunities of osteoarthritis industry
Exhibit 21: Five forces analysis
Exhibit 22: Global osteoarthritis pain drugs market segmentation by drug class
Exhibit 23: Some NSAIDs used to treat osteoarthritis pain
Exhibit 24: Global osteoarthritis pain drugs market shares by drug class 2015
Exhibit 25: Global osteoarthritis pain drugs market segmentation by drug class 2015-2020 ($ billions)
Exhibit 26: Global osteoarthritis pain drugs market segmentation by drug class 2015-2020 percentage
Exhibit 27: Global osteoarthritis pain drugs market 2015-2020
Exhibit 28: YoY growth rate of global osteoarthritis pain drugs market segments 2015-2020
Exhibit 29: Global NSAIDs market 2015-2020 ($ billions)
Exhibit 30: Global opioids market 2015-2020 ($ billions)
Exhibit 31: Global viscosupplements market 2015-2020 ($ billions)
Exhibit 32: Global corticosteroids market 2015-2020 ($ billions)
Exhibit 33: Global osteoarthritis pain drugs market segmentation by ROA
Exhibit 34: Global osteoarthritis pain drugs market segmentation by ROA 2015
Exhibit 35: Global osteoarthritis pain drugs market segmentation by dosage form
Exhibit 36: Global osteoarthritis pain drugs market segmentation by ROA 2015
Exhibit 37: Global osteoarthritis pain drugs market by geographical segmentation 2015
Exhibit 38: Global osteoarthritis pain drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 39: Global osteoarthritis pain drugs market revenue by geography 2015-2020
Exhibit 40: Global osteoarthritis pain drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 41: Osteoarthritis pain drugs market in Americas 2015-2020 ($ billions)
Exhibit 42: Osteoarthritis pain drugs market in Americas 2015
Exhibit 43: Osteoarthritis pain drugs market in US 2015-2020 ($ billions)
Exhibit 44: Osteoarthritis pain drugs market in EMEA 2015-2020 ($ billions)
<table>
<thead>
<tr>
<th>Exhibit</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>Osteoarthritis pain drugs market in APAC 2015-2020 ($ billions)</td>
</tr>
<tr>
<td>46</td>
<td>Unmet medical needs with current osteoarthritis pain treatments</td>
</tr>
<tr>
<td>47</td>
<td>Prevalence of osteoarthritis in 2012 and 2022 (millions)</td>
</tr>
<tr>
<td>48</td>
<td>Average annual prevalence of osteoarthritis in US</td>
</tr>
<tr>
<td>49</td>
<td>Incidence of osteoarthritis in overweight and normal weight individuals 2013</td>
</tr>
<tr>
<td>50</td>
<td>Worldwide estimated osteoarthritis population growth 2010-2020</td>
</tr>
<tr>
<td>51</td>
<td>Population aged 60 years and over: World, developed, and developing regions (millions)</td>
</tr>
<tr>
<td>52</td>
<td>Expected growth of older population in US 2010-2050</td>
</tr>
<tr>
<td>53</td>
<td>Impact of drivers</td>
</tr>
<tr>
<td>54</td>
<td>Alternative therapies for osteoarthritis pain</td>
</tr>
<tr>
<td>55</td>
<td>Use of CAM therapies among individuals in US</td>
</tr>
<tr>
<td>56</td>
<td>Impact of drivers and challenges</td>
</tr>
<tr>
<td>57</td>
<td>Future therapeutics in osteoarthritis pain treatment</td>
</tr>
<tr>
<td>58</td>
<td>Key takeaways</td>
</tr>
<tr>
<td>59</td>
<td>Key takeaways</td>
</tr>
<tr>
<td>60</td>
<td>Novartis: YoY revenue and growth rate of Voltaren 2013-2015 ($ millions)</td>
</tr>
<tr>
<td>61</td>
<td>Key takeaways</td>
</tr>
<tr>
<td>62</td>
<td>Pfizer: YoY revenue and growth rate of Celebrex 2013-2015 ($ millions)</td>
</tr>
<tr>
<td>63</td>
<td>Pfizer: Geographical segmentation of Celebrex 2015</td>
</tr>
<tr>
<td>64</td>
<td>Key takeaways</td>
</tr>
<tr>
<td>65</td>
<td>Flexion Therapeutics: Pipeline products</td>
</tr>
<tr>
<td>66</td>
<td>Kitov Pharmaceuticals: Pipeline products</td>
</tr>
<tr>
<td>67</td>
<td>Osteoarthritis pain market size model</td>
</tr>
</tbody>
</table>

Ordering:

- **Order Online** - [http://www.researchandmarkets.com/reports/3736336/](http://www.researchandmarkets.com/reports/3736336/)
- **Order by Fax** - using the form below
- **Order by Post** - print the order form below and send to

Research and Markets,  
Guinness Centre,  
Taylors Lane,  
Dublin 8,  
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Osteoarthritis Pain Market 2016-2020
Web Address: http://www.researchandmarkets.com/reports/3736336/
Office Code: SCH3YOX6

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td></td>
<td>USD 2500</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users:</td>
<td></td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td></td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in **BLOCK CAPITALS**

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:  
  You will receive an email with a link to a secure webpage to enter your credit card details.

- Pay by check:  
  Please post the check, accompanied by this form, to:
  Research and Markets,
  Guinness Center,
  Taylors Lane,
  Dublin 8,
  Ireland.

- Pay by wire transfer:  
  Please transfer funds to:
  Account number 833 130 83
  Sort code 98-53-30
  Swift code ULSBIE2D
  IBAN number IE78ULSB98533083313083
  Bank Address Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World